- Report
- October 2024
- 199 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 195 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 182 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 129 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 131 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 128 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 135 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- March 2025
- 93 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- August 2024
- 141 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- May 2024
- 137 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Drug Pipelines
- April 2024
- 250 Pages
Global
From €2852EUR$3,000USD£2,396GBP
- Report
- December 2024
- 144 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Clinical Trials
- May 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Drug Pipelines
- April 2024
- 50 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- January 2025
- 250 Pages
Global
From €4752EUR$4,999USD£3,992GBP
- Report
- December 2024
Europe, Global, Japan, ... Europe, Global, Japan, United States
From €17587EUR$18,500USD£14,775GBP
- Report
- February 2025
Japan, United States, ... Japan, United States, Europe, Global
From €3565EUR$3,750USD£2,995GBP
- Report
- December 2024
Canada, Mexico, North America Canada, Mexico, North America
From €9031EUR$9,500USD£7,587GBP

The Factor VIII market is a segment of the hematological drugs market, which includes drugs used to treat blood-related disorders. Factor VIII is a protein that helps blood to clot, and is used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Factor VIII is typically administered intravenously, and is available in both recombinant and plasma-derived forms.
The Factor VIII market is highly competitive, with a number of companies offering products. These include Novo Nordisk, Pfizer, Bayer, CSL Behring, and Shire. Additionally, there are several smaller companies that offer Factor VIII products, such as Octapharma, Kedrion, and Biotest. Show Less Read more